Adia Nutrition Reports Over 200% Quarterly Revenue Growth and Advances Toward Nasdaq Listing

Reuters
Nov 05, 2025
<a href="https://laohu8.com/S/ADIA">Adia Nutrition</a> Reports Over 200% Quarterly Revenue Growth and Advances Toward Nasdaq Listing

Adia Nutrition Inc. (OTCQB: ADIA) announced key business updates and financial results, highlighting significant growth and strategic progress in 2025. The company reported a revenue surge exceeding 200% quarter-over-quarter in the third quarter, with profit margins above 20%, attributed to strong demand for Adia Med clinics and Adia Labs regenerative products. Adia Nutrition has tripled its sales force and established four regional divisions to enhance nationwide and international distribution. The company also completed the divestiture of its non-core coffee subsidiary, Biolete Coffee, retaining an 18% equity stake. Additionally, Adia Nutrition is preparing to file its SEC Form 10 registration statement by the end of November 2025, aiming for full effectiveness by late January 2026 as part of its strategy to secure a Nasdaq listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273008) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10